Needham analyst Michael Matson maintained a Buy rating on Inogen (INGN – Research Report) today and set a price target of $47.00. The company's shares closed last Wednesday at $30.27, close to its 52-week low of $26.19. According to TipRanks.com, Matson is a 4-star analyst with an average return of 7.0% and a 54.7% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inogen with a $43.50 average price target. See Insiders’ Hot Stocks on TipRanks >> Inogen's market cap is currently $688.
https://www.tipranks.com/news/blurbs/needham-thinks-inogens-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral